Skip to content

Indication

Major Depressive Disorder

173 registered trials testing LSD, Psilocybin, Ketamine, DMT for this indication, 39 recruiting now.

Sponsors register this under 5 different names, all collected here: Depressive Disorder, Major · MDD · Major Depressive Disorder · Major Depressive Disorder (MDD · Major Depressive Disorder (MDD)

173
Registered trials
39
Recruiting
26
In Phase 3

Substances tested

Being studied with

Stay told

When a new trial opens

Research alerts

Get a notification when a trial for Major Depressive Disorder trials starts recruiting

This registry is rebuilt every day. If no trial is recruiting for you today, that can change within weeks.

This form sends your email address and the topic of this page to Brevo, our email provider, which stores them on servers in the European Union. We never sell that address, never share it with anyone, and never use it for advertising. One email deletes it. What is held, and where.

Trials

All 173 trials for Major Depressive Disorder

TrialStatusPhaseSubstanceSites
Positioning of Esketamine Treatment in the Real-world Management of DepressionNCT06103760 · Royal North Shore HospitalRecruitingPhase 4ketamine1
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With DepressionNCT05450432 · Massachusetts General HospitalRecruitingPhase 4ketamine1
Neural Circuit Effects of Ketamine in DepressionNCT06213324 · Icahn School of Medicine at Mount SinaiRecruitingPhase 4ketamine1
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderNCT06793397 · Cybin IRL LimitedRecruitingPhase 3psilocybin68
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive DisorderNCT06247839 · Sharmin GhaznaviRecruitingPhase 3psilocybin1
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)NCT07592689 · Definium Therapeutics US, Inc.RecruitingPhase 3lsd30
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454 · Janssen Research & Development, LLCRecruitingPhase 3ketamine35
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive DisorderNCT07703722 · Khyber Medical University PeshawarRecruitingPhase 3psilocybin3
Understanding and Treating Suicidal Ideation With KetamineNCT06891300 · The Royal's Institute of Mental Health ResearchRecruitingPhase 2 / Phase 3ketamine1
Ketamine Augmentation of ECT in Treatment-Resistant DepressionNCT07088380 · Università Vita-Salute San RaffaeleRecruitingPhase 3ketamine1
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment FailureNCT05603104 · Dr. Inge WinterRecruitingPhase 3ketamine1
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.NCT05973851 · Dr. Inge WinterRecruitingPhase 3ketamine12
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT)NCT07569198 · Joshua RosenblatRecruitingPhase 2ketamine1
A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and AnxietyNCT06820723 · Ohio State UniversityRecruitingPhase 2psilocybin1
Inhaled DMT for Major Depressive DisorderNCT07562191 · Universidade Federal do Rio Grande do NorteRecruitingPhase 2dmt5
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant DepressionNCT06511908 · National Institute of Mental Health (NIMH)RecruitingPhase 2ketamine1
Psilocybin Therapy for Psychological Distress in Palliative PatientsNCT06782724 · University Medical Center GroningenRecruitingPhase 2psilocybin4
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal EffectsNCT05786066 · Yale UniversityRecruitingPhase 2ketamine1
Cancer Related Major Depression Treated With a Single Dose of PsilocybinNCT06319378 · Section for Affective Disorders; Northern Stockholm PsychiatryRecruitingPhase 2psilocybin4
A Randomized Neuroimaging Trial of Psilocybin in DepressionNCT06072898 · Sunnybrook Health Sciences CentreRecruitingPhase 2psilocybin1
Imaging Depression in Parkinson's DiseaseNCT06402955 · Yale UniversityRecruitingPhase 2ketamine1
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or BehaviorNCT07193901 · Sichuan Purity Pharmaceutical Technology Co., Ltd.RecruitingPhase 2ketamine8
i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical TrialNCT06480500 · University Health Network, TorontoRecruitingPhase 2ketamine1
Psilocybin rTMS for Treatment Resistant DepressionNCT06132178 · University of Texas at AustinRecruitingPhase 2psilocybin1
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of DepressionNCT06559826 · Icahn School of Medicine at Mount SinaiRecruitingPhase 2ketamine1
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive DisorderNCT06592833 · Icahn School of Medicine at Mount SinaiRecruitingPhase 2psilocybin1
Pharmacologic Treatment Augmentation in Chronic DepressionNCT06410599 · University Hospital TuebingenRecruitingPhase 2ketamine2
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive DisorderNCT03065335 · National Institute of Mental Health (NIMH)RecruitingPhase 1ketamine1
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant DepressionNCT06480201 · Texas A&M UniversityRecruitingPhase 1ketamine2
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major DepressionNCT03973268 · National Institute of Mental Health (NIMH)RecruitingPhase 1ketamine1
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine ResponseNCT05915013 · Yale UniversityRecruitingPhase 1ketamine1
Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of KetamineNCT06788249 · University of PennsylvaniaRecruitingEarly Phase 1ketamine1
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With KetamineNCT05327699 · Emory UniversityRecruitingEarly Phase 1ketamine1
Antidepressant Response of DMT Masked With PropofolNCT06927076 · University Hospital, Basel, SwitzerlandRecruitingNot applicabledmt1
University of Iowa Interventional Psychiatry Service Patient RegistryNCT04480918 · Mark NiciuRecruitingN/Aketamine1
At-Home tDCS as Maintenance TherapyNCT07269964 · Technical University of MunichRecruitingNot applicableketamine2
Metabolic Profiling of Esketamine Treatment in Depressive DisorderNCT07002684 · University of ZagrebRecruitingN/Aketamine1
Digital Interventions for Adults with Treatment-Resistant Depression: a Pilot StudyNCT06732089 · Unity Health TorontoRecruitingN/Aketamine1
RIVER At Home Ketamine ProtocolsNCT06070766 · RIVER FoundationRecruitingN/Aketamine2
Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal ThoughtsNCT07139106 · New York State Psychiatric InstituteNot yet recruitingPhase 4ketamine1
Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for DepressionNCT05615948 · Theresa Jacob, PhD, MPHCompletedPhase 4ketamine1
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray TreatmentNCT04829318 · Janssen-Cilag Ltd.CompletedPhase 4ketamine59
Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant DepressionNCT05045378 · Taipei Veterans General Hospital, TaiwanCompletedPhase 4ketamine1
Ketamine-Assisted Mindfulness-Based Cognitive Therapy for Depression: A Pilot StudyNCT05950711 · Ohio State UniversityActive, not recruitingPhase 4ketamine1
VA Aripiprazole vs Esketamine for Treatment Resistant DepressionNCT05554627 · VA Office of Research and DevelopmentWithdrawnPhase 4ketamine26
Ketamine Treatment Effects on Synaptic Plasticity in DepressionNCT04091971 · New York State Psychiatric InstituteCompletedPhase 4ketamine1
Intraoperative Ketamine Versus Saline in Depressed Patients Undergoing Anesthesia for Non-cardiac SurgeryNCT03861988 · Stanford UniversityCompletedPhase 4ketamine1
An EEG Study of Intravenous Ketamine for Major Depression DisorderNCT05506462 · Ehave Inc.Unknown statusPhase 4ketamine
Intra-nasal vs. Intra-venous Ketamine AdministrationNCT02644629 · Shalvata Mental Health CenterCompletedPhase 4ketamine1
Ketamine Infusion for Adolescent Depression and AnxietyNCT02579928 · Yale UniversityCompletedPhase 4ketamine2
Study to Assess the Effects of Intranasal Ketamine Along With rTMS for Patients With Treatment-resistant Major Depressive Disorder (TRD)NCT04352621 · University of CincinnatiUnknown statusPhase 4ketamine
Ketamine in the Treatment of Suicidal DepressionNCT01700829 · New York State Psychiatric InstituteCompletedPhase 4ketamine1
Ketamine for Depression: An MRI StudyNCT02544607 · Massachusetts General HospitalCompletedPhase 4ketamine1
N-methyl-D-aspartate Antagonist (Ketamine) Augmentation of Electroconvulsive Treatment for Severe Major DepressionNCT01260649 · Massachusetts General HospitalTerminatedPhase 4ketamine1
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"NCT06564818 · Cybin IRL LimitedActive, not recruitingPhase 3psilocybin45
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)NCT06941844 · Definium Therapeutics US, Inc.Active, not recruitingPhase 3lsd22
Psilocybin for Major Depressive Disorder (MDD)NCT06308653 · Usona InstituteActive, not recruitingPhase 3psilocybin29
Opiate Suicide Study in Patients With Major DepressionNCT04116528 · Stanford UniversityCompletedPhase 3ketamine1
Predictors of Intravenous Ketamine Response in TRDNCT05625555 · Abraham NunesActive, not recruitingPhase 3ketamine1
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03039192 · Janssen Research & Development, LLCCompletedPhase 3ketamine56
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03097133 · Janssen Research & Development, LLCCompletedPhase 3ketamine61
A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive DisorderNCT04338321 · Janssen-Cilag International NVCompletedPhase 3ketamine171
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)NCT03113968 · Bo HuCompletedPhase 2 / Phase 3ketamine5
Ketamine Versus Electroconvulsive Therapy in DepressionNCT03674671 · University of OttawaSuspendedPhase 3ketamine4
Ketamine for Severe Adolescent Depression: Intermediate-term Safety and EfficacyNCT03889756 · Yale UniversityTerminatedPhase 2 / Phase 3ketamine1
ECT vs. EsketamineNCT04924257 · Medical University InnsbruckWithdrawnPhase 3ketamine1
The Effect of Ketamine on Mechanises Underlying Suicidal Ideation and Drug-resistant Major DepressionNCT02037503 · Tel-Aviv Sourasky Medical CenterUnknown statusPhase 3ketamine1
Endogenous Opioid Modulation by KetamineNCT03051945 · University of UtahWithdrawnPhase 3ketamine1
Ketamine as an Alternative Treatment to ECT in Major Depressive DisorderNCT02659085 · Pouya Movahed RadCompletedPhase 2 / Phase 3ketamine1
Estimate the Efficiency of the Association of an Injection of Ketamine and the Venlafaxine in the Severe Major Depressive Disorder for Six WeeksNCT01557712 · University Hospital, GrenobleCompletedPhase 3ketamine1
An Open Prospective Trial of IV Ketamine in Suicidal AdolescentsNCT02048423 · Nationwide Children's HospitalUnknown statusPhase 2 / Phase 3ketamine1
Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of PsilocybinNCT06341426 · University Health Network, TorontoActive, not recruitingPhase 2psilocybin2
A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major DepressionNCT07396272 · Daniel LindqvistActive, not recruitingPhase 2ketamine1
Psilocybin for Treatment-Resistant DepressionNCT06230757 · University of Colorado, DenverCompletedPhase 2psilocybin1
Two Doses of Psilocybin for the Treatment of MDD in Adults With CancerNCT05947383 · Sunstone MedicalActive, not recruitingPhase 2psilocybin1
A Study of Psilocybin for Major Depressive Disorder (MDD)NCT03866174 · Usona InstituteCompletedPhase 2psilocybin11
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use DisorderNCT04620759 · Johns Hopkins UniversityActive, not recruitingPhase 2psilocybin1
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use DisorderNCT07405606 · Centre for Addiction and Mental HealthNot yet recruitingPhase 2psilocybin1
Microdosing Psychedelics to Improve MoodNCT05259943 · Rotem PetrankerCompletedPhase 2psilocybin1
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality DisorderNCT05399498 · University of ChicagoCompletedPhase 2psilocybin1
Ketamine-Enhanced Therapy for Individuals With Alcohol Use Disorder and Depression: A Pilot Study (KET-DUAL)NCT07247370 · South West Sydney Local Health DistrictNot yet recruitingPhase 1 / Phase 2ketamine1
Effect of Psilocybin Only and Psilocybin Assisted Cognitive Behavioral Therapy in the Management of Major Depressive Disorder and Associated Metabolic, Immune, Inflammatory, Neuroplasticity and Electrical Activity MarkersNCT06746441 · Khyber Medical University PeshawarCompletedPhase 2psilocybin1
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive DisorderNCT05733546 · COMPASS PathwaysActive, not recruitingPhase 2psilocybin5
Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic TargetsNCT05046184 · University of Texas Southwestern Medical CenterCompletedPhase 2ketamine1
A Study of Ketamine in Patients With Treatment-resistant DepressionNCT01627782 · Janssen Research & Development, LLCCompletedPhase 2ketamine13
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant DepressionNCT01640080 · Janssen Research & Development, LLCCompletedPhase 2ketamine9
A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for SuicideNCT02133001 · Janssen Research & Development, LLCCompletedPhase 2ketamine14
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819 · Janssen Research & Development, LLCCompletedPhase 2ketamine51
LSD Therapy for Persons Suffering From Major DepressionNCT03866252 · University Hospital, Basel, SwitzerlandCompletedPhase 2lsd1
Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use DisorderNCT02461927 · VA Office of Research and DevelopmentCompletedPhase 1 / Phase 2ketamine1
Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative MechanismsNCT03429075 · Imperial College LondonCompletedPhase 2psilocybin1
Psilocybin for Major Depressive DisorderNCT05675800 · Washington University School of MedicineWithdrawnPhase 2psilocybin
KAP for Depression in Abstinent Opioid UsersNCT05193318 · Medical University of South CarolinaTerminatedPhase 2ketamine1
The Effect of Psilocybin on MDD Symptom Severity and Synaptic DensityNCT04630964 · Section for Affective Disorders; Northern Stockholm PsychiatryCompletedPhase 2psilocybin1
SPL026 (DMT Fumarate) in Healthy Subjects and MDD PatientsNCT04673383 · Small Pharma LtdCompletedPhase 1 / Phase 2dmt2
A Study of a Psilocybin Analog (CYB003) in Healthy Participants With and Without Major Depressive DisorderNCT05385783 · Cybin IRL LimitedCompletedPhase 1 / Phase 2psilocybin3
Ketamine Treatment for PTSD and MDD in TBINCT06228391 · Minneapolis Veterans Affairs Medical CenterNot yet recruitingPhase 2ketamine1
Ketamine or Placebo in Patients With Major Depression and Advanced CancerNCT04471818 · Instituto Nacional de Cancerologia de MexicoCompletedPhase 1 / Phase 2ketamine1
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of SuicideNCT04669665 · Seelos Therapeutics, Inc.CompletedPhase 2ketamine21
Open Label Ketamine Treatment for Major Depressive Disorder in VeteransNCT03053830 · VA Connecticut Healthcare SystemCompletedPhase 2ketamine1
Clinical Study of GH001 in DepressionNCT04698603 · GH Research Ireland LimitedCompletedPhase 1 / Phase 2dmt1
Effect of SSRIs on Response to Psilocybin TherapyNCT05594667 · Cybin Therapeutics Inc.WithdrawnPhase 2psilocybin1
PET Synaptogenesis After Psilocybin In DEpression RecoveryNCT05601648 · Washington University School of MedicineWithdrawnPhase 2psilocybin1
miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment OutcomeNCT02418195 · University of Alabama at BirminghamCompletedPhase 2ketamine1
Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of ConceptNCT03715127 · University of ZurichCompletedPhase 2psilocybin1
Effects of Psilocybin in Major Depressive DisorderNCT03181529 · Johns Hopkins UniversityCompletedPhase 2psilocybin1
The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive DisorderNCT04593563 · Maryland Oncology Hematology, PAUnknown statusPhase 2psilocybin1
The UTHealth Ketamine ProjectNCT02882711 · The University of Texas Health Science Center, HoustonTerminatedPhase 2ketamine1
Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant DepressionNCT03965858 · Celon Pharma SACompletedPhase 2ketamine12
Ketamine in Adolescents With Treatment-Resistant DepressionNCT02078817 · University of MinnesotaCompletedPhase 2ketamine1
Ketamine in the Treatment of DepressionNCT01558063 · Columbia UniversityCompletedPhase 2ketamine1
Naltrexone Plus Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use DisorderNCT03658330 · VA Connecticut Healthcare SystemCompletedPhase 2ketamine
A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive DisorderNCT01957410 · Janssen Research & Development, LLCTerminatedPhase 2ketamine1
Optimization of IV Ketamine for Treatment Resistant DepressionNCT00768430 · Baylor College of MedicineCompletedPhase 2ketamine2
Study of Ketamine as an Antidepressant in Major Depressive DisorderNCT01573741 · Shi JinyunUnknown statusPhase 1 / Phase 2ketamine1
Psilocybin-assisted CBT for DepressionNCT05227612 · University of California, Los AngelesCompletedPhase 1psilocybin1
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive DisorderNCT03554174 · Yale UniversityActive, not recruitingPhase 1psilocybin1
Fixed Order, Open-Label, Dose-Escalation Study of DMT in HumansNCT04711915 · Yale UniversityActive, not recruitingPhase 1dmt1
Repeated Ketamine Infusions for Comorbid PTSD and MDD in VeteransNCT04032301 · University of MinnesotaCompletedPhase 1ketamine1
A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive DisorderNCT02919579 · Janssen Research & Development, LLCCompletedPhase 1ketamine1
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot TrialNCT03367533 · Yale UniversityCompletedPhase 1ketamine1
SPL026 With or Without SSRIs in Participants With MDDNCT05553691 · Small Pharma LtdCompletedPhase 1dmt2
Phase 1 Evaluation of (2R,6R)-HydroxynorketamineNCT04711005 · National Institute of Mental Health (NIMH)CompletedPhase 1ketamine1
The Effect of Ketamine on Aesthetics and Role for Antidepressant EffectsNCT05320107 · Medical University of ViennaUnknown statusPhase 1ketamine1
IM and IV SPL026 Drug Product in Healthy ParticipantsNCT05644093 · Small Pharma LtdCompletedPhase 1dmt1
Imaging Neural Correlates of Ketamine Using PET/MRNCT04587778 · Medical University of ViennaUnknown statusPhase 1ketamine1
The Role of HNKs in the Antidepressant Effect of KetamineNCT03977675 · Columbia UniversityTerminatedPhase 1ketamine1
Ketamine for Relapse Prevention in Recurrent Depressive DisorderNCT02661061 · St Patrick's Hospital, IrelandTerminatedPhase 1ketamine1
Biomarkers of Fast Acting Therapies in Major DepressionNCT02165449 · University of California, Los AngelesCompletedPhase 1ketamine1
Ketamine for Major Depressive DisorderNCT03721900 · Shenox Pharmaceuticals, LLCUnknown statusPhase 1ketamine3
Continuation Ketamine in Major DepressionNCT00548964 · James MurroughCompletedPhase 1ketamine1
Mood Effects of Serotonin Agonists: DepressionNCT07017478 · University of ChicagoCompletedEarly Phase 1lsd1
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:NCT03573349 · Mayo ClinicActive, not recruitingEarly Phase 1ketamine1
Ketamine for Mood Disorders With Suicidal IdeationNCT04099771 · The Miriam HospitalUnknown statusEarly Phase 1ketamine1
A Multimodal Neuroimaging Study of Brain Activation Patterns Under KetamineNCT03609190 · Psychiatric University Hospital, ZurichCompletedEarly Phase 1ketamine
Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.NCT02593643 · Sunnybrook Health Sciences CentreCompletedEarly Phase 1ketamine1
Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic PsychedelicsNCT06624137 · Yale UniversityTerminatedN/Alsd, psilocybin, dmt2
Imaging SV2A in Mood DisordersNCT02734602 · Yale UniversityActive, not recruitingNot applicableketamine1
Multimodal Pharmacological Study of Clinical Cohorts for Major Depressive DisorderNCT07602153 · Shanghai Mental Health CenterNot yet recruitingN/Aketamine
PSIL201 Long-term Follow-up Study: Psilocybin or Niacin / Major Depressive DisorderNCT04353921 · Usona InstituteTerminatedN/Apsilocybin1
Electroconvulsive Therapy Versus Intravenous Ketamine in Treatment-Resistant Major Depressive DisorderNCT07526454 · Tanta UniversityCompletedNot applicableketamine1
Mitochondrial Function After KetamineNCT07399756 · Sheba Medical CenterNot yet recruitingN/Aketamine1
Comparison of Propofol and Ketofol as Induction Agents for Electroconvulsive TherapyNCT07273851 · Fauji Foundation HospitalCompletedNot applicableketamine1
Retrospective Observational Study of Intensity Effects in Psychedelic-assisted TreatmentNCT07164287 · University Hospital, GenevaActive, not recruitingN/Alsd, psilocybin1
Behavioural Activation Therapy and Esketamine for Resistant DepressionNCT06431386 · The Royal's Institute of Mental Health ResearchTerminatedNot applicableketamine1
Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)NCT05565352 · Medical University of GdanskEnrolling by invitationN/Aketamine1
Synaptic Imaging and Network Activity in Treatment Resistant DepressionNCT05870501 · King's College LondonCompletedNot applicableketamine1
Behavioral and Electrophysiological Effects of Ketamine in Treatment-Resistant DepressionNCT04239963 · Mclean HospitalCompletedN/Aketamine1
Brain Network Dynamics of Depression During Esketamine TreatmentNCT06012916 · University of North Carolina, Chapel HillCompletedN/Aketamine1
Chart Review of Patients Undergoing Ketamine InfusionsNCT04209296 · Brain and Cognition Discovery FoundationCompletedN/Aketamine1
Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant DepressionNCT06232291 · Medical University of GdanskCompletedN/Aketamine1
Glutamate Emotion Memory StudyNCT05809609 · University of OxfordUnknown statusNot applicableketamine1
A Naturalistic Study of Ketamine for Treatment Resistant Mood DisordersNCT04226963 · Medical University of GdanskCompletedN/Aketamine1
Naturalistic Study of Ketamine in the Treatment of DepressionNCT05249309 · Hospital de Clinicas de Porto AlegreUnknown statusN/Aketamine2
Reward Emotion Learning and Ketamine StudyNCT04850911 · University of OxfordUnknown statusNot applicableketamine1
Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in DepressionNCT04701866 · Douglas Mental Health University InstituteCompletedNot applicableketamine2
Add-on Therapy With Edupression.Com® on Therapy Resistant Depressive Patients Treated With Nasal Esketamine SprayNCT04843462 · Lukas PezawasUnknown statusNot applicableketamine1
Esketamine Adjuvant Therapy for Patients With Chronic Visceral Pain Comorbid Major Depressive DisorderNCT04847245 · Peking UniversityUnknown statusNot applicableketamine
Ketamine IV Classic Protocol : Five Years Follow upNCT04824157 · Sheba Medical CenterCompletedN/Aketamine1
The Effect of S-ketamine for Patients Undergoing Electroconvulsive Therapy (ECT)NCT04399070 · Yan QiuUnknown statusNot applicableketamine1
Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant DepressionNCT03027362 · Yale UniversityCompletedNot applicableketamine1
Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant DepressionNCT02522377 · The Cleveland ClinicCompletedNot applicableketamine1
Ketamine for Treatment Resistant MDDNCT04021433 · Hadassah Medical OrganizationUnknown statusNot applicableketamine1
Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and SuicideNCT03666390 · Taipei Veterans General Hospital, TaiwanUnknown statusNot applicableketamine1
Ketamine Anesthesia for Improvement of Depression in ECTNCT02752724 · VA Puget Sound Health Care SystemCompletedNot applicableketamine1
Ketamine and Scopolamine Infusions for Treatment-resistant Major Depressive DisorderNCT01613820 · Massachusetts General HospitalWithdrawnNot applicableketamine1
Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive SymptomsNCT02422303 · The University of Texas Health Science Center at San AntonioTerminatedNot applicableketamine1
PET Imaging of mGLuR5 With Drug ChallengeNCT01691092 · Yale UniversityCompletedNot applicableketamine3
Ketamine Infusion for Treatment-resistant Major Depressive DisorderNCT01582945 · Massachusetts General HospitalCompletedNot applicableketamine1
Ketamine Versus Placebo for Treatment Resistant Major Depressive DisorderNCT01667926 · Massachusetts General HospitalCompletedNot applicableketamine1
MRI Studies of Emotion in DepressionNCT02429011 · Icahn School of Medicine at Mount SinaiCompletedN/Aketamine1
Intranasal Ketamine in Treatment-Resistant DepressionNCT01304147 · James MurroughCompletedNot applicableketamine1
Ketamine Infusions for Major Depression DisorderNCT02219867 · Sheba Medical CenterUnknown statusNot applicableketamine1

Records from ClinicalTrials.gov API v2, data build 2026-08-25. Indications are the sponsors’ own words. LSD.com reports registered clinical research. It is not medical advice, it is not a recommendation to take any substance, and trial listings are not endorsements. Talk to a clinician.